Navigation Links
Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
Date:1/25/2009

180 Patient Trial of 2nd Generation Oxazolidinone Enrolls in Four Months

SAN DIEGO, Jan. 26 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the completion of enrollment in its randomized, double-blind Phase 2 clinical trial testing the oral dosage form of torezolid (also known as TR-701) in patients with complicated skin and skin structure infections (cSSSI). The trial, which was conducted in 12 clinical sites in the United States, examined the efficacy and safety of three dosage strengths of torezolid administered orally once daily over a 5-7 day course of treatment. Top line results of the Phase 2 trial are expected in the second quarter of this year.

"The rapid enrollment in this trial is not only a testimony to the diligence and competence of our clinical investigators and colleagues, but is also an indicator of the increasing prevalence of bacterial infections caused by MRSA in our hospitals and communities and the potential for an oral drug to confront this epidemic," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "Over 90% of the pathogens infecting patients enrolled in our Phase 2 trial were Staphylococcus aureus, of which nearly 70% were MRSA. Oral torezolid appears well tolerated and effective as a once-daily therapy to quickly eradicate MRSA and other Gram-positive bacteria causing complicated skin infections."

"Having initiated Phase 1 testing of torezolid in January of 2008, it is very encouraging to have advanced the program through Phase 2 enrollment in approximately one year," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We aim to continue this momentum and advance the intravenous dosage form of torezolid through Phase 1 testing this year and to initiate Phase 3 testing of both the intravenous and oral dosage forms shortly thereafter. Our goal is to offer patients and physicians a 'best-in-class' therapeutic option to address the growing unmet
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
11. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... JUNCTION, N.J. , Nov. 21, 2014 /PRNewswire/ ... company commercializing its European Union approved CytoSorb® cytokine ... worldwide, was awarded the Beacon of Light Award ... Awards Celebration.  Dr. Phillip ... "It is an honor to be recognized by ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... diagnostic tests, has appointed Juliet Cunningham as ... Cunningham will be responsible for driving communications with the ... on a series of changes to increase shareholder value, ... to investors," said Namal Nawana, Chief Executive Officer. "We ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2
... organiser UBM Live , a division of UBM ... and Supply Chain Zone to be introduced at ICSE ... outsourcing. ICSE will take place from October 25-27, 2011 ... the world,s leading platform of pharmaceutical events, including CPhI ...
... GRAND RAPIDS, Mich., May 31, 2011 The ... announced the opening of a first-of-its-kind genomic-based clinical ... specifically relapsed and refractory neuroblastoma. ... Institute (VARI), is a nationwide network of pediatric ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3Consortium Opens Landmark Personalized Medicine Children's Cancer Trial 2
(Date:11/23/2014)... To show thanks to new and old ... white evening dresses for weddings. Customers who need ... iFitDress.com is a distinguished dress manufacturer, and it is among ... customers for a very long time. The CEO of this ... will be able to buy not only a beautiful dress, ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 AngelWeddingDress.com ... worldwide a new selection of beach wedding dresses. “If ... best prices, visit AngelWeddingDress.com as soon as possible. Here ... workmanship.” The sales manager says. , Holding a big ... girl. And choosing a beautiful beach wedding dress is ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
(Date:11/23/2014)... , the world’s leader in bamboo flooring, has recently released ... Now, the business is announcing big discounts on these new ... until Dec. 20, 2014. , The new click strand woven ... makes it very easy to maintain. As one of the ... its website the best shopping platform for people who are ...
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2
... 'Bigorexic'? No, its not another eating disorder, it's just ... Bruce Davies, of the University of Glamorgan //says that ... faced by people suffering from anorexia and bulimia. ... drugs to counteract their altered body images," he said. ...
... in the Bombay High Court today raised the issue of spurious ... curb the trade of such drugs. // ,The High ... this regard by July 12., ,The PIL was filed by ... spurious injection of the drug `Imipenam' at KEM hospital in Pune ...
... Zealand report low levels of perceived security at school, ... a new survey//. ,The Youth 2000 national survey, ... Auckland University, asked 922 Asian students about their mental ... ,Chinese and Indian students made up the ...
... fat in abdomen, hip and upper thighs through liposuction which ... a liquid and is sucked out. // ,Liposuction ... special instruments and technique are used to liquefy the fat ... the fatty areas. Since it is practically non-invasive it is ...
... doctor, Dr.S.Raja Sabapathy, has been appointed honorary consultant and ... speciality of plastic, hand and reconstructive micro surgery. // ... of surgery in Ganga Medical Centre and Hospitals, would ... of armed forces across the country, an hospital release ...
... a very common cancer which has very poor prognosis. This is ... spread in the body//. The spread of cancer cells in the ... in case of cancer patients as it blocks vital organs, blood ... and treatment of cancer patients improves their survival rate. But good ...
Cached Medicine News:Health News:Indian Students in New Zealand Feel Insecure 2Health News:IMP3 the Novel Biomarker for Metastatic Cancer 2Health News:IMP3 the Novel Biomarker for Metastatic Cancer 3
The Elisa test is used for the detection and semi-quantitative determination of IgG, antibodies to myeloperoxidase in human sera as an aid to the diagnosis is of microscopic polyangiitis....
... this Enzyme ImmunoAssay (EIA) is as follows: ... on a 96 well microtiter plate. After ... the trapped molecule is covalently linked to ... After washing and denaturing treatment, Angiotensin II ...
... a solid phase two-site enzyme immunoassay. ... sandwich technique in which two monoclonal ... determinants on the insulin molecule. During ... with peroxidase-conjugated anti-insulin antibodies and anti-insulin ...
... SAS RSV antigen test is ... for the presumptive qualitative detection ... from nasopharyngeal specimens in neonatal ... 15 minute test has a ...
Medicine Products: